Enanta Pharmaceuticals (ENTA) Operating Income Growth (1y) (2013 - 2026)

Enanta Pharmaceuticals (ENTA) Operating Income Growth (1y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 8.32%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 19.82%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 145.20%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 269.85%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 76.24%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -36.55%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 1,528.74%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 99.51%
10 Enanta Pharmaceuticals 383.29 Mn 193.78 Mn - 8.77%

Historic Data

Download Data
DateValue
Jun 30, 2026 8.77%
Mar 31, 2026 51.68%
Dec 31, 2025 52.20%
Sep 30, 2025 38.41%
Jun 30, 2025 21.88%
Mar 31, 2025 25.14%
Dec 31, 2024 32.51%
Sep 30, 2024 3.79%
Jun 30, 2024 34.12%
Mar 31, 2024 16.95%
Dec 31, 2023 -16.24%
Sep 30, 2023 -14.72%
Jun 30, 2023 -12.82%
Mar 31, 2023 -16.56%
Dec 31, 2022 1.30%
Sep 30, 2022 19.80%
Jun 30, 2022 3.86%
Mar 31, 2022 -13.96%
Dec 31, 2021 -147.25%
Sep 30, 2021 -70.48%